HealthQuill INPEFA
Cytokinetics, a US-based biopharmaceutical company, announced the FDA had rejected its new drug application for approving a trial drug to treat heart problems with reduced ejection fraction (HFrEF).
Drugs Health Pharma

FDA approves Lexicon’s oral drug for heart failure, type 2 diabetes patients

INPEFA is an inhibitor of both sodium-glucose co-transporter type 2 (SGLT2) and type 1 (SGLT1). This class of SGLT inhibitors was recommended as.

Read More
X